These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22133146)
1. Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL. Leong S; McKay MJ; Christopherson RI; Baxter RC J Proteome Res; 2012 Feb; 11(2):1240-50. PubMed ID: 22133146 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225 [TBL] [Abstract][Full Text] [Related]
3. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632 [TBL] [Abstract][Full Text] [Related]
4. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. Lai TC; Chou HC; Chen YW; Lee TR; Chan HT; Shen HH; Lee WT; Lin ST; Lu YC; Wu CL; Chan HL J Proteome Res; 2010 Mar; 9(3):1302-22. PubMed ID: 20052998 [TBL] [Abstract][Full Text] [Related]
5. iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL. Leong S; Nunez AC; Lin MZ; Crossett B; Christopherson RI; Baxter RC J Proteome Res; 2012 Jul; 11(7):3561-72. PubMed ID: 22587632 [TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
7. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300 [TBL] [Abstract][Full Text] [Related]
8. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385 [TBL] [Abstract][Full Text] [Related]
9. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Xu J; Zhou JY; Tainsky MA; Wu GS Cancer Res; 2007 Feb; 67(3):1203-11. PubMed ID: 17283156 [TBL] [Abstract][Full Text] [Related]
10. Proteome changes induced by overexpression of the p75 neurotrophin receptor (p75NTR) in breast cancer cells. Wilmet JP; Tastet C; Desruelles E; Ziental-Gelus N; Blanckaert V; Hondermarck H; Le Bourhis X Int J Dev Biol; 2011; 55(7-9):801-9. PubMed ID: 22161836 [TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Chopin V; Slomianny C; Hondermarck H; Le Bourhis X Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702 [TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
13. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836 [TBL] [Abstract][Full Text] [Related]
14. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037 [TBL] [Abstract][Full Text] [Related]
15. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
16. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463 [TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Xu J; Zhou JY; Wu GS Cancer Res; 2006 Oct; 66(20):10092-9. PubMed ID: 17047073 [TBL] [Abstract][Full Text] [Related]
18. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741 [TBL] [Abstract][Full Text] [Related]
20. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]